ArticleJournal of ophthalmic inflammation and infection2026
Hydroxychloroquine in the treatment of sarcoidosis-associated uveitis and idiopathic uveitis.
Article in Journal of ophthalmic inflammation and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential therapeutic applications of stem cells in animal models of ocular affections.Inflammation and regeneration · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUveitis is a major cause of blindness in developed countries, and adverse effects associated with long-term use of topical or systemic steroids and immunosuppressive agents are notable. This study aimed to evaluate the efficacy and safety of hydroxychloroquine (HCQ) in sarcoidosis-associated uveitis (SAU) and idiopathic uveitis (IdU).
methodsThis monocentric retrospective study included 42 patients with SAU and 15 patients with IdU treated with HCQ for at least six months between March 2003 and December 2022. All types of uveitis were included. Most patients had chronic bilateral granulomatous SAU or IdU. Efficacy was determined by the success rate of HCQ at 6 and 12 months, and at the last visit and was defined as having control of inflammation, no more than 5 mg prednisone daily and less than or equal to 2 drops of dexamethasone phosphate 0.1%, and no treatment failure due to safety. Biomicroscopic data, best-corrected visual acuity, inflammation grading (SUN criteria) and optionally data from optical coherence tomography and fluorescein or indocyanine green angiography were assessed. The Fisher's exact test and the Wilcoxon rank test were used for the comparison of qualitative data and quantitative data respectively. Prednisone dose was compared using a mixed model.
resultsThe median [IQR] duration to the last visit was 19.5 [11-44.8] months in SAU patients and 18 [13-38] months in IdU patients. At the last visit, 55% of patients with SAU (including 70% of anterior SAU and 77% of intermediate SAU) and 40% patients with IdU (including 27% of anterior IdU) were successfully treated with HCQ ; the median [IQR] prednisone dose decreased from 10 [8.0-27.5] to 4 [2.5-5.75] mg/day and from 15.5 [12.5-19.5] to 3.0 [3.0-5.0] mg/day in SAU and IdU patients, respectively. The reduction in median prednisone dose was significant in patients with SAU (p = 0.002). The incidence rate ratio of flare was 0.73 (p = 0.143) in SAU patients and 0.26 (p < 0.001) in IdU patients.
conclusionHCQ could be an interesting therapeutic option for specific types of SAU and IdU. Additionally, HCQ decreased the incidence of flare-ups and the need for oral prednisone in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.